Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.174
Sell
RSI(14)
38.390
Neutral
STOCH(KDJ)(9,3,3)
9.750
Oversold
ATR(14)
0.243
Low Volatility
CCI(14)
-76.588
Neutral
Williams %R
93.388
Oversold
TRIX(12,20)
-0.574
Sell
StochRSI(14)
10.144
Sell
Gain Therapeutics Inc
GANX1.745USD
-0.085-4.64%
Market hours （ET）Quotes delayed by 15 min
19.77MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Gain Therapeutics Inc
Currency: USD Updated: 2026-03-27Key Insights
Gain Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 133 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.60.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Gain Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Gain Therapeutics Inc Highlights
StrengthsRisks
Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of glucocerebrosidase or GCase, function in the lysosome, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.
Undervalued
The company’s latest PE is -2.99, at a low 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 569.90K shares of this stock.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
7.600
Target Price
+302.12%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-03-27The current financial score of Gain Therapeutics Inc is 6.75, ranking 209 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.27
Operational Efficiency
2.70
Growth Potential
6.75
Shareholder Returns
7.03
Gain Therapeutics Inc's Company Valuation
Currency: USD Updated: 2026-03-27The current valuation score of Gain Therapeutics Inc is 6.10, ranking 327 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.99, which is -76.12% below the recent high of -0.71 and -129.72% above the recent low of -6.87.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 133/391
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-03-27The current earnings forecast score of Gain Therapeutics Inc is 8.80, ranking 51 out of 391 in the Biotechnology & Medical Research industry. The average price target is 7.00, with a high of 8.00 and a low of 5.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
7.600
Target Price
+302.12%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
548
Total
6
Median
6
Average
Company name
Ratings
Analysts
Gain Therapeutics Inc
GANX
5
CRISPR Therapeutics AG
CRSP
29
IQVIA Holdings Inc
IQV
27
argenx SE
ARGX
26
Beigene Ltd
ONC
24
Intellia Therapeutics Inc
NTLA
24
1
2
3
...
110
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-03-27The current price momentum score of Gain Therapeutics Inc is 6.55, ranking 202 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.68 and the support level at 1.36, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.886
Sell
MA10
2.037
Sell
MA20
2.381
Sell
MA50
2.131
Sell
MA100
2.550
Sell
MA200
2.156
Sell
Institutional Confidence
Currency: USD Updated: 2026-03-27The current institutional shareholding score of Gain Therapeutics Inc is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 12.80%, representing a quarter-over-quarter decrease of 0.11%. The largest institutional shareholder is The Vanguard, holding a total of 569.90K shares, representing 1.48% of shares outstanding, with 67.05% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Marshall Wace LLP
Islam (Khalid)
Edward Jones
Susquehanna International Group, LLP
Cambridge Investment Research Advisors, Inc.
Geode Capital Management, L.L.C.
Richman (Eric I.)
1
2
Risk Assessment
Currency: USD Updated: 2026-03-27The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Gain Therapeutics Inc is 1.70, ranking 285 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.10. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
0.19
VaR
+7.39%
240-Day Maximum Drawdown
+61.24%
240-Day Volatility
+107.85%
Return
Best Daily Return
60 days
+31.10%
120 days
+31.10%
5 years
+31.10%
Worst Daily Return
60 days
-25.57%
120 days
-44.44%
5 years
-44.44%
Sharpe Ratio
60 days
-1.22
120 days
+0.71
5 years
+0.04
Risk Assessment
Maximum Drawdown
240 days
+61.24%
3 years
+81.89%
5 years
+91.13%
Return-to-Drawdown Ratio
240 days
+0.14
3 years
-0.26
5 years
-0.18
Skewness
240 days
-0.29
3 years
-0.15
5 years
+0.01
Volatility
Realised Volatility
240 days
+107.85%
5 years
+100.82%
Standardised True Range
240 days
+11.31%
5 years
+15.01%
Downside Risk-Adjusted Return
120 days
+95.77%
240 days
+95.77%
Maximum Daily Upside Volatility
60 days
+86.72%
Maximum Daily Downside Volatility
60 days
+83.16%
Liquidity
Average Turnover Rate
60 days
+1.15%
120 days
+1.06%
5 years
--
Turnover Deviation
20 days
+25.68%
60 days
+6.76%
120 days
-2.09%
Peer Comparison
Biotechnology & Medical Research
Gain Therapeutics Inc
GANX
6.14 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Day One Biopharmaceuticals Inc
DAWN
8.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.21 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
